The Potential of Transient Receptor Potential Vanilloid Type 1 Channel Modulators for the Treatment of Pain
- 1 May 2007
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (11) , 2589-2596
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Design of Potent, Orally Available Antagonists of the Transient Receptor Potential Vanilloid 1. Structure−Activity Relationships of 2-Piperazin-1-yl-1H-benzimidazolesJournal of Medicinal Chemistry, 2006
- The transient receptor potential vanilloid 1: Role in airway inflammation and diseaseEuropean Journal of Pharmacology, 2006
- Identification and Biological Characterization of 6-Aryl-7-isopropylquinazolinones as Novel TRPV1 Antagonists that Are Effective in Models of Chronic PainJournal of Medicinal Chemistry, 2005
- Proton Activation Does Not Alter Antagonist Interaction with the Capsaicin-Binding Pocket of TRPV1Molecular Pharmacology, 2005
- Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbilsBritish Journal of Pharmacology, 2005
- Development of the First Ultra-Potent “Capsaicinoid” Agonist at Transient Receptor Potential Vanilloid Type 1 (TRPV1) Channels and Its Therapeutic PotentialThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Cloning and pharmacological characterization of mouse TRPV1Neuroscience Letters, 2004
- Neurogenic responses mediated by vanilloid receptor‐1 (TRPV1) are blocked by the high affinity antagonist, iodo‐resiniferatoxinBritish Journal of Pharmacology, 2003
- The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic PainThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin ReceptorScience, 2000